Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jeffrey Yourshaw

Interventional Cardiology High Point, NC Medical Doctor

NPI 1003109869 CMS profile 363289

306 Westwood Ave, High Point, NC 27262

Open in the dashboard

General payments

$11,479

148 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jeffrey Yourshaw of High Point, NC is reported in the CMS Open Payments database as having received $11,479 across 148 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 62nd percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $875 9
2024 General $1,178 11
2023 General $1,798 23
2022 General $755 16
2021 General $2,006 34
2020 General $3,590 39
2019 General $1,277 16

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jeffrey Yourshaw
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Jeffrey Yourshaw were reported at $875. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Jeffrey Yourshaw Interventional Cardiology median Middle half National median
2019 $1,277 $1,097 $329–$3,048 $163
2020 $3,590 $473 $161–$1,480 $114
2021 $2,006 $677 $233–$1,827 $132
2022 $755 $978 $333–$2,724 $149
2023 $1,798 $1,136 $382–$2,986 $160
2024 $1,178 $1,181 $395–$3,326 $164
2025 $875 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $3,020 42 payments
  2. Medtronic, Inc. $1,775 22 payments
  3. Abiomed $1,487 17 payments
  4. Edwards Lifesciences Corporation $1,370 8 payments
  5. Boston Scientific Corporation $812 23 payments
  6. Medtronic Vascular, Inc. $575 7 payments
  7. Neptune Medical Inc. $487 1 payment
  8. Shockwave Medical, Inc $412 3 payments
  9. LivaNova USA, Inc. $374 4 payments
  10. Cardiovascular Systems Inc. $305 7 payments
  11. Other $863 14 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,039 137 payments
  2. Travel and Lodging $1,903 9 payments
  3. Consulting Fee $487 1 payment
  4. Education $50 1 payment
Products named General payments · program years 2019–2025
  1. Edwards SAPIEN 3 Transcatheter Heart Valve $1,370 8 payments
  2. Impella $1,195 15 payments
  3. Xience Sierra Coronary Stent System Cardiac Arrhythmias and Heart Failure $1,122 14 payments
  4. MC3 NAUTILUS(TM) ECMO OXYGENATOR $1,089 12 payments
  5. FLOWTRIEVER CATHETER, S $462 2 payments
  6. Resolute $385 5 payments
  7. Optis Coronary Imaging System $378 6 payments
  8. Xience Sierra Coronary Stent System Vascular $371 8 payments
  9. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter $330 2 payments
  10. AMPLATZER TALISMAN $281 2 payments
  11. Other $3,947 72 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

236

Median for Cardiology: 2,533

Drug cost

$29,417

Median for Cardiology: $485,213

Branded share of claims

36%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 11 $15,461
Entresto Sacubitril/Valsartan Brand 18 $11,896
Ranolazine Er Ranolazine Brand 13 $585
Atorvastatin Calcium Generic 32 $382
Isosorbide Mononitrate Er Isosorbide Mononitrate Brand 24 $266
Nitroglycerin Generic 20 $178
Ezetimibe Generic 13 $155
Amlodipine Besylate Generic 26 $144
Rosuvastatin Calcium Generic 27 $136
Clopidogrel Clopidogrel Bisulfate Brand 19 $73

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 68 billing codes

Paid by Medicare

$117,465

Medicare's payments for the services billed

Medicare patients

664

Average age 72

Services billed

1,365

305 women, 359 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 53%
Arthritis 48%
Heart failure 46%
Chronic kidney disease 40%
Diabetes 38%
Atrial fibrillation 35%
Depression 24%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

148 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record